TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) Investor Investigation Over Potential Wrongdoing Announced

  • Investors who purchased shares of Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) have certain options and should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Investigation Overview

Company
Aevi Genomic Medicine, Inc.
Security
NASDAQ: GNMX

Summary

An investigation on behalf of investors in shares of Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) was announced over potential breaches of fiduciary duties by certain officers and directors at Aevi Genomic Medicine, Inc.

The investigation by a law firm concerns whether certain Aevi Genomic Medicine directors breached their fiduciary duties and caused damage to the company and its shareholders.

Wayne, PA based Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States.

Aevi Genomic Medicine, Inc reported that its Net Loss declined from $41.9 million in 2016 to $34.71 million in 2017.

Shares of Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) declined from $6.18 per share in March 2017 to as low as $0.98 per share in late May 2017.

Start Monitoring Your Investments